About site: Pharmacy/Drugs and Medications/T/Tositumomab - Bexxar - GSK

Return to Health also Health

About site: http://www.bexxar.com/ Title: Pharmacy/Drugs and Medications/T/Tositumomab - Bexxar - GSK Official Pharmaceutical website for patients, caregivers, and health professionals.

Apligraf_Skin_Graft Manufacturer's site for this product, providing information including for medical professionals, including how the product is made, case studies, efficacy results, and tips for using the product. Celebrex A source of information about relief from arthritis pain including Osteoarthritis and Rheumatoid Arthritis. A nonsteroidal anti-inflammatory drug, product information is provided. Celebrex Full prescribing information from RxList. DrugDigest__Celecoxib_(_Celebrex_) Information on dosage, usage, side effects, interactions, and drug comparisons. Food_and_Drug_Administration_(FDA)_-_Celebrex_Consumer_Information Patient FAQ in html format with a link to approved labeling (as pdf). CNS_Manifestations_of_Nasu-Hakola_Disease__A_Frontal_Dementia_with_Bone_Cysts Abstract of paper by Paloneva et al.   Alexa statistic for http://www.bexxar.com/ Please visit: http://www.bexxar.com/

Related sites for http://www.bexxar.com/     Loss-of-function_mutations_in_TYROBP_(DAP12)_result_in_a_presenile_dementia_with_bone_cysts Paper in Nature Genetics by Paloneva et al describing the discovery of the genetic defect causing Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.     Online_Mendelian_Inheritance_in_Man Population genetics, references, and symptoms of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, also known as Nasu-Hakola disease, and as presenile dementia with bone cy     NutrActive\'s_Fitness_Center Personalized fitness programs for all levels of fitness. Covers numerous topics including weight loss, dieting, exercise and fitness.     ToxNetwork_com Consulting and litigation support in toxicology, carcinogenesis, pharmacology, and pharmacy standard of care. Rockville, Maryland.     ToxSeek Metasearch and Clustering Engine for Environmental Health and Toxicology from the National Library of Medicine.     Fdg Full prescribing information from RxList.     Congenital_Deafness_and_Its_Recognition Highly technical paper concerning congenital hearing loss in cats and dogs from a veterinary perspective.     Deafness_in_Dogs_and_Cats Information about the condition, including an article describing the association of congenital deafness with white coat color.     Genetics_and_the_White_Cat Several articles concerning congenital hearing loss with a focus on the Norwegian Forest Cat.     The_Pigment_Parade Discussion of the association of impaired hearing with white inheritance and blue eye color.     Roy_Robinson_on_White_Cats Article by the late Roy Robinson on the association of congenital hearing loss with whiteness and blue eye color.     DrugDigest__Valtrex Information on dosage, usage, side effects, interactions, and drug comparisons.     Valtrex Full prescribing information from RxList.     Valtrex Valtrex is indicated for the treatment or suppression of genital herpes for adults with normal immune systems. (Valacyclovir)     Valtrex_(_valcyclovir_HCl_) Contains information about genital herpes and treatment options from Glaxo Wellcome.     Anesthesia_Associates_of_Pinellas_County Outlines the practice based at Morton Plant Hospital. Provides backgrounds for the groups physicians, descriptions of services provided, information on billing.     Anesthesia_Consultants_of_California_Medical_Group Describes the group's practice. Links to anesthesia societies provided.     Anesthesia_Consultants_of_the_South A group of board-certified anesthesiologists providing comprehensive anesthesia care in New Orleans, Louisiana.     Anesthesia_Service_Medical_Group Outlines a San Diego, CA anesthesia practice. Lists physicians, facilities, billing policies.     Anesthesia_Services,_P_A_ Describes a large group practice located in northern Delaware, affiliated with the Christiana Care Health System. Outlines the anesthesia care team, monitoring, anesthetic concerns for different type     Anesthesiology_for_Dentistry Dr. Davies provides hospital grade anesthesia services in Southern California dental offices.     Associated_Anesthesiologists_Medical_Group Gives information on physicians, insurances accepted, and facilities for the San Jose, California anesthesia group. Provides links to patient education sites.     Brevard_Anesthesia_Services Anesthesia and pain management services for central Florida. Describes practice, and facilities.     Bristol_Anesthesia_Services Outlines the anesthesia practice located in Bristol, Tennessee. Provides backgrounds for the group's physicians and its health information privacy policy.     Chichster_Anaesthetics_Group Provides information about anaesthetic procedures and options as well as information about the group, its members and the services it provides. Located in Chichester, West Sussex, England.     Columbia_Anesthesia_Associates Board Certified and Board Eligible anesthesiologists who practice anesthesiology and pain management at multiple ambulatory surgical centers and facilities.     Cosmetic_Surgery_Anesthesia Dr. Barry Friedberg, in Corona del Mar, California. Practice information, propofol ketamine techniques, research, contacts.     Critical_Health_Systems_,_Wake_Practice_Center Providing anesthesia services in Wake County, currently work in the three WakeMed facilities. Find organization details, employment opportunities, student info and contact details. Located in Raleigh,     Eau_Claire_Anesthesiologists,_Ltd_ Care team of anesthesiologist and anesthetist who work together to provide the medical care during surgery as well as relief during postoperative hospital stay. Details about the physicians, billing,     Linn_County_Anesthesiologists Anesthesia practice for Cedar Rapids, Iowa including physician listing, financial policies, links to hospitals, and frequently asked questions.     Midwest_Physician_Anesthesia_Services Outlines the clinic's anesthesia services and includes FAQs.     Millennium_Anesthesia_Care Doctors, hospitals and services. Tampa, Florida.     Peridural_com Focuses on the possibilities of ultrasound imaging for regional anesthesia.     Reading_Anesthesia_Associates,_Ltd_ Contains information for patients about anesthesia techniques and options, including pediatrics and obstetrics, as well as information about our professional group, its sites of operation and practice     South_Shore_Anesthesia_Associates Provides 24-hour critical care coverage for South Shore Hospital. Find information about the physicians and nurses, a patient guide, resources, and contact details. Located in Weymouth, Massachusetts.     Targ_Mobile_Anesthesia Provides portable services for dental offices, with brochures available for downloading in Spanish, Mandarin, Japanese, Vietnamese and English. Includes credentials and patient information.     DrugDigest__Famciclovir_(_Famvir_) Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.     Famvir_(Famciclovir) Full prescribing information from RxList.     Dolobid Full prescribing information from RxList.     Birthroot_Midwifery_Services Northern Indiana and Southwest Michigan. Lynn McDonald offers maternity and well-woman gynecological services.

This is sites2007.com cache of m/ as retrieved on 2012.02.09 sites2007.com's cache is the snapshot that we took of the page as we crawled the web. The page may have changed since that time.

Bexxar Homepage Prescribing Information for BEXXAR (including boxed WARNINGS) BLACK BOX WARNINGS Hypersensitivity Reactions, Including Anaphylaxis: Serious hypersensitivity reactions, including some with fatal outcome, have been reported with the BEXXAR therapeutic regimen. Medications for the treatment of severe hypersensitivity reactions should be available for immediate use. Patients who develop severe hypersensitivity reactions should have infusions of the BEXXAR therapeutic regimen discontinued and receive medical attention (see WARNINGS in the complete Prescribing Information). Black Box Warning and Important Safety Information Continued Below Download Prescribing Information If you are a patient or a caregiver and want to learn more about BEXXAR:Visit patient Web siteDownload Patient Education BrochureDownload complete Prescribing Information INDICATION The BEXXAR® therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin’s lymphoma, including patients with Rituximab-refractory non-Hodgkin’s lymphoma.  Determination of the effectiveness of the BEXXAR therapeutic regimen is based on overall response rates in patients whose disease is refractory to chemotherapy alone or to chemotherapy and Rituximab. The effects of the BEXXAR therapeutic regimen on survival are not known. The BEXXAR therapeutic regimen is not indicated for the initial treatment of patients with CD20-positive non-Hodgkin’s lymphoma. The BEXXAR therapeutic regimen is intended as a single course of treatment. The safety of multiple courses of the BEXXAR therapeutic regimen, or combination of this regimen with other forms of irradiation or chemotherapy, has not been evaluated. COMPLETE BOXED WARNINGS AND ADDITIONAL IMPORTANT SAFETY INFORMATION FOR BEXXAR BLACK BOX WARNINGS Hypersensitivity Reactions, Including Anaphylaxis: Serious hypersensitivity reactions, including some with fatal outcome, have been reported with the BEXXAR therapeutic regimen. Medications for the treatment of severe hypersensitivity reactions should be available for immediate use. Patients who develop severe hypersensitivity reactions should have infusions of the BEXXAR therapeutic regimen discontinued and receive medical attention (see WARNINGS in the complete Prescribing Information). Prolonged and Severe Cytopenias: The majority of patients who received the BEXXAR therapeutic regimen experienced severe thrombocytopenia and neutropenia. The BEXXAR therapeutic regimen should not be administered to patients with >25% lymphoma marrow involvement and/or impaired bone marrow reserve (see WARNINGS and ADVERSE REACTIONS in the complete Prescribing Information). Pregnancy Category X: The BEXXAR therapeutic regimen can cause fetal harm when administered to a pregnant woman. Special Requirements: The BEXXAR therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) contains a radioactive component and should be administered only by physicians and other healthcare professionals qualified by training in the safe use and handling of therapeutic radionuclides. The BEXXAR therapeutic regimen should be administered only by physicians who are in the process of being or have been certified by GlaxoSmithKline in dose calculation and administration of the BEXXAR therapeutic regimen. CONTRAINDICATIONS The BEXXAR® therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is contraindicated in patients with known hypersensitivity to murine proteins or any other component of BEXXAR. BEXXAR is contraindicated for use in women who are pregnant. ADDITIONAL IMPORTANT SAFETY INFORMATION Data regarding adverse events were primarily obtained in 230 patients with non-Hodgkin’s lymphoma enrolled in 5 clinical trials. Data from 765 patients enrolled in an expanded access program were used to supplement the characterization of delayed adverse events. Prolonged and Severe Cytopenias: The majority of patients, 71% of 230, who received the BEXXAR therapeutic regimen, experienced severe or life-threatening (Grade 3/4) cytopenias. The most common were Grade 3/4 thrombocytopenia (53%) and Grade 3/4 neutropenia (63%). Time to nadir was 4-7 weeks, lasting approximately 30 days. Due to the variable nature of the onset of the cytopenias, complete blood counts should be obtained weekly for 10-12 weeks. More frequent monitoring is indicated in patients with evidence of moderate or more severe cytopenias. Blood counts should be monitored weekly until severe cytopenias have resolved. Sequelae included infections (45%), hemorrhage (12%), and requirement for hematological supportive care (27%). Hypersensitivity Reactions, Including Anaphylaxis: Serious hypersensitivity reactions, including some with fatal outcome, were reported during and following administration of BEXXAR.  Patients who have received murine proteins should be screened for human anti-mouse antibodies (HAMA) as they may be at increased risk for anaphylaxis and serious hypersensitivity reactions during administration of BEXXAR. In clinical studies, 6% (14) of 230 patients experienced one or more hypersensitivity reactions. Secondary Leukemia, Myelodysplastic Syndrome (MDS), and Secondary Malignancies: At a median follow-up of 29 months, 44 cases of myelodysplastic syndrome and/or secondary leukemia were reported in 995 patients enrolled in clinical studies and an expanded access program. Additional malignancies (65 cases) were also reported in 54 of the patients. Approximately half of these were nonmelanomatous skin cancers (26). The remainder, which occurred in 2 or more patients, included colorectal cancer, head and neck cancer, breast cancer, lung cancer, bladder cancer, melanoma, and gastric cancer, in order of decreasing incidence. The relative risk of developing secondary malignancies in patients receiving BEXXAR over the background rate in this population cannot be determined due to the absence of controlled studies. Hypothyroidism: Administration of BEXXAR may result in hypothyroidism. Thyroid-blocking medications should be initiated at least 24 hours before receiving the dosimetric dose and continued until 14 days after the therapeutic dose. All patients must receive thyroid-blocking agents; any patient who is unable to tolerate thyroid-blocking agents should not receive BEXXAR. Patients should be evaluated for signs and symptoms of hypothyroidism and screened for biochemical evidence of hypothyroidism annually. Of the 230 patients in the clinical studies, 203 did not have elevated thyroid-stimulating hormones (TSH) upon study entry. Of these, 137 patients had at least 1 posttreatment TSH value available and were not taking thyroid hormonal treatment upon study entry. With a median follow-up period of 46 months, the incidence of hypothyroidism based on elevated TSH or initiation of thyroid replacement therapy in these patients was 18%, with a median time to development of hypothyroidism of 16 months. The cumulative incidences of hypothyroidism at 2 and 5 years in these 137 patients were 11% and 19%, respectively. New events have been observed up to 90 months posttreatment. Patients With Impaired Renal Function: Iodine I 131 Tositumomab and Iodine-131 are excreted primarily by the kidneys. Impaired renal function may decrease the rate of excretion of the radiolabeled iodine and increase patient exposure to the radioactive component of the BEXXAR therapeutic regimen. There are no data regarding the safety of administration of BEXXAR in patients with impaired renal function. Immunization: The safety of immunization with live viral vaccines following administration of BEXXAR has not been studied. The ability of patients who have received BEXXAR to generate a primary or anamnestic humoral response to any vaccine has not been studied. Carcinogenesis, Mutagenesis, Impairment of Fertility: Radiation is a potential carcinogen and mutagen. There is a potential risk that BEXXAR may cause toxic effects on the male and female gonads. Effective contraceptive methods should be used during treatment and for 12 months following administration of BEXXAR. Nursing Mothers: Radioiodine is excreted in breast milk and may reach concentrations equal to or greater than maternal plasma concentrations. Immunoglobulins are also known to be excreted in breast milk. The absorption potential and potential for adverse effects of the monoclonal antibody component (Tositumomab) in the infant are not known. Therefore, formula feedings should be substituted for breast feedings before starting treatment. Women should be advised to discontinue nursing. Adverse Reactions: The most serious adverse reactions observed in the clinical trials were severe and prolonged cytopenias and the sequelae of cytopenias which included infections (sepsis) and hemorrhage in thrombocytopenic patients, allergic reactions (bronchospasm and angioedema), secondary leukemia and myelodysplasia. The most common adverse reactions occurring in the clinical trials included neutropenia (63%), thrombocytopenia (53%), and anemia (29%) that were both prolonged and severe (NCI CTC grade 3 or 4). Less common but severe adverse reactions included pneumonia (6%), pleural effusion (<5%) and dehydration (<5%). Infusional Toxicities: Infusional toxicities including fever, rigors, chills, sweating, nausea, hypotension, dyspnea, and bronchospasm have been reported during and/or following the infusion of BEXXAR. In the clinical studies, fever, rigors, chills, or sweating were reported in 67 patients (29%) within 14 days following the dosimetric dose. Infusional toxicities were managed by slowing and/or temporarily interrupting the infusion. Adjustments occurred in 7% of the patients and included reduction in the rate of infusion by 50%, temporary interruption of the infusion, and in 2 patients, infusion was permanently discontinued. Immunogenicity (HAMA): Administration of BEXXAR may result in the development of HAMA. Of the 230 patients in the clinical studies, 220 were seronegative for HAMA prior to treatment and 219 had at least 1 posttreatment HAMA value obtained. With a median observation period of 6 months, 23 patients (11%) became seropositive for HAMA posttreatment. The median time of HAMA development was 6 months. The cumulative incidences of HAMA seropositivity at 6 months, 12 months, and 18 months were 6%, 17%, and 21%, respectively. The presence of HAMA may affect the toxicity and/or efficacy of in vivo diagnostic or therapeutic agents that rely on murine antibodies and may affect the accuracy of in vitro and in vivo diagnostic tests.  Assessment of Biodistribution: The biodistribution of Iodine I 131 Tositumomab should be assessed. If biodistribution is altered, the therapeutic dose should not be administered. You are encouraged to report negative side effects of prescription drugs to the FDA.Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.     This website is funded and developed by GlaxoSmithKline.This site is intended for US residents only.© 1997-2012 GlaxoSmithKline. All Rights Reserved.Legal Notices | Privacy Statement | Medicine Savings | Contact Us var omni_pageName = "Bexxar Homepage"; var omni_channel = "Landing"; var omni_pagetype = ""; /* You may give each page an identifying name, server, and channel on the next lines. */ if (omni_pageName == ""){ s.prop35=location.href } else { s.pageName = omni_pageName } if (omni_pagetype == "ErrorPage") { s.channel = "" } else if (omni_channel == ""){ s.channel = "No Channel Defined" } else { s.channel = omni_channel } s.events="" s.pageType=omni_pagetype s.eVar1=s.pageName s.prop9=s.pageName + " " + s.campaign /************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/ var s_code=s.t();if(s_code)document.write(s_code)//-->

Official Pharmaceutical website for patients, caregivers, and health professionals. Warning: fsockopen() [function.fsockopen]: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/content/s/i/t/sites2007/html/page.php on line 131 Warning: fsockopen() [function.fsockopen]: unable to connect to http:80 in /home/content/s/i/t/sites2007/html/page.php on line 131 Success ERROR: Success (0)